CABA Stock Summary and Trading Ideas (Cabaletta Bio | NASDAQ:CABA)

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Cabaletta Bio trades on the NASDAQ stock market under the symbol CABA.

As of February 7, 2025, CABA stock price climbed to $2.65 with 1,420,084 million shares trading.

CABA has a market cap of $129.45 million. This is considered a Micro Cap stock.

In the last 3 years, CABA traded as high as $26.35 and as low as $.59.

The top ETF exchange traded funds that CABA belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

CABA has underperformed the market in the last year with a return of -88.8%, while the SPY ETF gained +22.0%. In the last 3 month period, CABA fell short of the market, returning -42.1%, while SPY returned +1.2%. However, in the most recent 2 weeks CABA has outperformed the stock market by returning +6.0%, while SPY returned -1.2%.

CABA support price is $2.42 and resistance is $2.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CABA shares will trade within this expected range on the day.